Most Undervalued Biological Products, (No Diagnostic Substances) Stocks 2026

Top undervalued Biological Products, (No Diagnostic Substances) stocks in 2026 ranked by Bayesian DCF implied upside. 13-model institutional analysis updated daily.

129 stocks analyzed Updated 2026-05-29
# Ticker Company QOC Price DCF Upside
1 SCLX Scilex Holding Company 4.7 $8.90 +463.5%
2 MRNA Moderna, Inc. 7.1 $47.19 +177.6%
3 QNCX Quince Therapeutics, Inc. 4.3 $1.15 +106.7%
4 BCRX BioCryst Pharmaceuticals, Inc. 6.9 $8.91 +66.7%
5 CGEN Compugen Ltd. 9.0 $2.63 +54.7%
6 HALO Halozyme Therapeutics, Inc. 10.0 $66.54 +13.2%
7 IMA ImageneBio, Inc. 5.8 $5.88 +11.4%
8 INAB IN8bio, Inc. 3.2 $1.87 -17.5%
9 VIVS VivoSim Labs, Inc. 4.5 $1.31 -19.7%
10 PLX Protalix BioTherapeutics, Inc. 7.6 $2.11 -21.2%
11 N••• Neurocrine ••••• •.• $•••.•• ••.•%
12 I••• Intensity ••••• •.• $•••.•• ••.•%
13 B••• Biogen ••••• •.• $•••.•• ••.•%
14 C••• Creative ••••• •.• $•••.•• ••.•%
15 T••• TScan ••••• •.• $•••.•• ••.•%
16 P••• Passage ••••• •.• $•••.•• ••.•%
17 Z••• Zura ••••• •.• $•••.•• ••.•%
18 T••• Bio-Techne ••••• •.• $•••.•• ••.•%
19 G••• Gilead ••••• •.• $•••.•• ••.•%
20 D••• Precision ••••• •.• $•••.•• ••.•%
🔒

Unlock the Full Most Undervalued Biological Products, (No Diagnostic Substances) Stocks 2026 List

Screen all 129 Biological Products, (No Diagnostic Substances) stocks with 13 institutional-grade valuation models. Updated daily from SEC EDGAR filings.

Access Full Screening — From $27/mo →

How CirclFi Ranks Biological Products, (No Diagnostic Substances) Stocks

CirclFi analyzes 129 Biological Products, (No Diagnostic Substances) stocks daily using 13 independent institutional-grade valuation models. Each model processes SEC EDGAR 10-K and 10-Q financial filings (700+ XBRL tags), FRED macroeconomic data, and GDELT news sentiment.

The most undervalued biological products, (no diagnostic substances) stocks 2026 ranking uses dcf upside as the primary sort criterion. Models span intrinsic valuation (Bayesian DCF with 10,000 Monte Carlo simulations, EPV), scenario analysis (First Chicago), regime-switching (Markov DDM), and machine learning (ML-RIV, FTNN Topology).